$VCYT

Bhanji Muna sold $80K of VCYT

Bhanji Muna sold 1,864 shares of VERACYTE, INC. (VCYT) at $42.97 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bhanji Muna
Published Sep 3, 2026, 8:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VCYT
Neutral
high confidence
Mentioned
$VCYT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCYTNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect investor sentiment significantly.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data could offset any negative perception from the sale.

Relevance 2/10Novelty 3/10Timing: filing date 2026-09-01

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on director holdings.

Company-level read

Ticker impact

$VCYTNeutralHigh confidence
Context

Director Bhanji Muna sold 1,864 shares for $80,096 via a 10b5-1 plan on 2026-09-01.

Expected impact

Minimal, likely <0.5% price dip if any.

Evidence & confidence

The sale amount is modest relative to holdings and market cap; director sales are routine.

Market effects

No broader sector impact; biotech sector unchanged.

Limited to US market, negligible regional effect.

None

Counterpoint

Insider may be diversifying; sale does not imply lack of confidence.

Key entities

  • Veracyte, Inc.

    NASDAQ-listed genomic diagnostics firm.

  • Bhanji Muna

    Director of Veracyte.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VCYTHigh

VERACYTE, INC. (VCYT): Results of Operations and Financial Condition

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS